Reuters logo
BRIEF-Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial
December 7, 2017 / 12:17 PM / in 4 days

BRIEF-Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial

Dec 7 (Reuters) - Heat Biologics Inc:

* SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL

* HEAT BIOLOGICS - RECEIVED WRITTEN RESPONSES FROM U.S. FDA REGARDING HS-110 TRIAL DESIGN FOR TREATMENT OF NON-SMALL CELL LUNG CANCER

* HEAT BIOLOGICS - FDA AGREED THAT TRIAL DESIGNS, BOTH SINGLE-ARM AND CONTROLLED, WOULD BE APPROPRIATE TO SUPPORT REGISTRATIONAL TRIAL OF HS-110

* HEAT BIOLOGICS - TRIAL DESIGN DETAILS AND NEXT STEPS EXPECTED TO BE ANNOUNCED FOLLOWING READ-OUT OF PHASE 2 DATA, ANTICIPATED IN 2H 2018 Source text : (bit.ly/2j13Nke) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below